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myocarditis
Abstract
RATIONALE: Myocardial fibrosis is a hallmark of inflammation-triggered end-stage heart disease, a
common cause of heart failure in young patients. OBJECTIVE: We used CD4(+) T-cell-mediated
experimental autoimmune myocarditis model to determine the parameters regulating cardiac fibrosis in
inflammatory heart disease. METHODS AND RESULTS: alpha-Myosin heavy chain peptide/complete
Freund's adjuvant immunization was used to induce experimental autoimmune myocarditis in BALB/c
mice. Chimeric mice, reconstituted with enhanced green fluorescence protein (EGFP)(+) bone marrow,
were used to track the fate of inflammatory cells. Prominin-1(+) cells were isolated from the inflamed
hearts, cultured in vitro and injected intracardially at different stages of experimental autoimmune
myocarditis. Transforming growth factor (TGF)-beta-mediated fibrosis was addressed using
anti-TGF-beta antibody treatment. Myocarditis peaked 21 days after immunization and numbers of
cardiac fibroblasts progressively increased on follow-up. In chimeric mice, >60% of cardiac fibroblasts
were EGFP(+) 46 days after immunization. At day 21, cardiac infiltrates contained approximately 30%
of prominin-1(+) progenitors. In vitro and in vivo experiments confirmed that prominin-1(+) but not
prominin-1(-) cells isolated from acutely inflamed hearts represented the cellular source of cardiac
fibroblasts at late stages of disease, characterized by increased TGF-beta levels within the myocardium.
Mechanistically, the in vitro differentiation of heart-infiltrating prominin-1(+) cells into fibroblasts
depended on TGF-beta-mediated phosphorylation of Smad proteins. Accordingly, anti-TGF-beta
antibody treatment prevented myocardial fibrosis in immunized mice. CONCLUSIONS: Taken
together, heart-infiltrating prominin-1(+) progenitors are the major source of subsequent
TGF-beta-triggered cardiac fibrosis in experimental autoimmune myocarditis. Recognizing the critical,
cytokine-dependent role of bone marrow-derived progenitors in cardiac remodeling might result in
novel treatment concepts against inflammatory heart failure.
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Abstract 
Background Myocardial fibrosis is a hallmark of inflammation-triggered end-stage heart 
disease, a common cause of heart failure in young patients.  
Objectives We used CD4+ T cell-mediated experimental autoimmune myocarditis (EAM) 
model to determine the parameters regulating cardiac fibrosis in inflammatory heart disease. 
Methods Alpha-myosin heavy chain peptide/complete Freund’s adjuvant immunization was 
used to induce EAM in BALB/c mice. Chimeric mice, reconstituted with enhanced green 
fluorescence protein (EGFP)+ bone marrow were used to track the fate of inflammatory cells. 
Prominin-1+ cells were isolated from the inflamed hearts, cultured in vitro and injected 
intracardially at different stages of EAM. TGF-β-mediated fibrosis was addressed using anti-
TGF-β antibody treatment.  
Results Myocarditis peaked 21 days after immunization and numbers of cardiac fibroblasts 
progressively increased on follow-up. In chimeric mice, >60% of cardiac fibroblasts were 
EGFP+ 46 days after immunization. At day 21, cardiac infiltrates contained about 30% of 
prominin-1+ progenitors. In vitro and in vivo experiments confirmed, that prominin-1+, but not 
prominin-1- cells, isolated from acutely inflamed hearts represented the cellular source of 
cardiac fibroblasts at late stages of disease, characterized by increased TGF-β levels within 
the myocardium. Mechanistically, the in vitro differentiation of heart-infiltrating prominin-1+ 
cells into fibroblasts depended on TGF-β-mediated phosphorylation of Smad proteins. 
Accordingly, anti-TGF-β antibody treatment prevented myocardial fibrosis in immunized 
mice. 
Conclusions Taken together, heart-infiltrating prominin-1+ progenitors are the major source 
of subsequent TGF-β-triggered cardiac fibrosis in EAM. Recognizing the critical, cytokine-
dependent role of bone marrow-derived progenitors in cardiac remodelling might result in 
novel treatment concepts against inflammatory heart failure. 
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Non-standard Abbreviations and Acronyms 
EAM-Experimental Autoimmune Myocarditis  
αMyHC-alpha Myosin Heavy Chain  
CEM-Culture Expansion Medium  
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Introduction 
Cardiac inflammation is most commonly triggered by viral infections. Virus-triggered 
myocarditis leading to inflammatory cardiomyopathy represents the most common cause of 
chronic heart failure in young patients. Heart-infiltrating inflammatory cells include 
granulocytes, monocytes, T cells, B cells, and mast cells, releasing various cytokines such as 
interleukin (IL)-17, -6, -1, -10, -12, interferon (IFN)-γ, transforming growth factor (TGF)-β, 
tumor necrosis factor (TNF)-α, chemokines, and matrix metalloproteinases/tissue inhibitors of 
matrix metalloproteinases1-6. Inflamed hearts are at increased risk to undergo pathological 
remodelling, which may finally result in heart failure and the phenotype of inflammatory 
dilated cardiomyopathy. This process is associated with disruption of normal myocardial 
structures, and extracellular matrix deposition promoting tissue fibrosis7,8.  
Experimental autoimmune myocarditis (EAM) is a CD4+ T cell-mediated mouse 
model of inflammatory cardiomyopathy. EAM can be induced in susceptible mouse strains by 
immunization with cardiac specific peptides derived from alpha myosin heavy chain 
(αMyHC)9, or cardiac troponin I10, together with a strong adjuvant or by injection of activated 
bone marrow-derived dendritic cells loaded with heart-specific self peptide9,11. In general, 
grading of EAM severity scores bases on the extent of inflammatory infiltrates at the peak of 
inflammation. In the ensuing late phase of disease, cardiac inflammation slowly resolves. 
However, many of the affected hearts show progressive dilation and increasing tissue fibrosis 
upon follow-up2.  
Insight from ischemic heart disease models suggests that the transition from acute 
inflammation to fibrosis is mediated by TGF-β8. Along this line, resolution of inflammation 
and progressive remodelling are associated with high levels of TGF-β in the myocardium12,13. 
TGF-β promotes the synthesis of various cytokines and growth factors, that are involved in 
formation/progression of cardiac fibrosis8. In contrast, the cause of cardiac fibrosis in the 
context of inflammatory heart disease remains unclear. Bone marrow (BM)-derived progenitor 
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cells recruited to the inflamed heart represent a potential cellular source for fibrosis14,15, but 
this idea is largely speculative. In particular, the role of BM-derived progenitor cells in the 
process of regeneration/pathological remodeling in EAM is unknown.  
Here we show that prominin-1+ progenitor cells represent a subpopulation of heart-
infiltrating BM-derived CD45+ cells at the peak of inflammation in EAM. These cells 
represent a common progenitor source for both fibroblasts and monocytes/macrophages, and 
play a critical role in the pathogenesis of cardiac fibrosis, a hallmark of end-stage heart 
failure. Fibroblast differentiation of prominin-1+ cells was promoted during the late stage of 
EAM due to a progressive shift of the intra-cardiac cytokine balance, reflected by increasing 
TGF-β levels.  
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Material and Methods 
 
Mice  
BALB/c and C57Bl/6-EGFP mice (Enhanced Green Fluorescent Protein-EGFP under the 
control of β-actin promoter) were purchased from Jackson Laboratory. C57Bl/6-EGFP mice 
were backcrossed onto the BALB/c background for >10 generations (hereafter referred to as 
BALB/c-EGFP). The local authorities approved the animal protocol and all experiments were 
performed in accordance with Swiss Federal Law.  
 
In vitro expansion/differentiation of heart-infiltrating prominin-1+ cells 
Mouse hearts were processed as described previously16. Prominin-1+ cells were isolated by 
magnetic cell sorting and further expanded in vitro in Culture Expansion Medium (CEM; 
Supplement Material). To generate single cell derived clones, a single prominin-1+/EGFP+ cell 
was co-plated with prominin-1+/EGFP- feeder cells derived from the healthy heart, and 
cultured for 2-3 weeks. Cardiac differentiation was induced with 100µM oxytocin (Sigma, 
Basel, Switzerland); macrophage differentiation- with 10ng/mL macrophage-colony 
stimulating factor (M-CSF) (PeproTech, London, UK); fibroblast differentiation- with 
10ng/mL TGF-β (PeproTech). 
 
Immunization and treatment protocols 
6-8 weeks old mice were injected subcutaneously with 150 µg/mouse of αMyHC (Ac-HN-
SLKLMATLFSTYASAD-OH, Caslo) emulsified 1:1 with complete Freund’s adjuvant 
(CFA)/PBS on days 0 and 7, as descibed6. Control mice were immunized with CFA/PBS 
only. Prominin-1+/EGFP+ cells were injected either directly into the left ventricle of 
anesthetized animals (5x104 cells per mouse) 0, 14 or 32 days after immunization using a 
Hamilton micro-syringe; or intravenously (1x106 cells per mouse) at days 7 and 14 after 
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immunization.  
A neutralizing monoclonal antibody α-TGF-β (clone1D11; R&D Systems) was used at 15 
µg/ml for in vitro experiments. For in vivo neutralization, mice received intraperitoneal 
injections of α-TGF-β (20 µg in 100 µl of PBS) or mouse IgG1 isotype control antibody 
every 3rd day between days 17-46 after αMyHC/CFA immunization.  
 
Generation of chimera  
6-8 weeks old BALB/c mice were lethally irradiated with 2x6.5 Gy using a Gammatron (Co-
60) system, and reconstituted with 2x107 donor BM cells from BALB/c-EGFP mice (hereafter 
referred to as EGFP->BALB/c; Supplement Material).  
 
Histology  
Depending on the experiment, animals were sacrificed at day 21, 32 and 46 after the first 
immunization. Hearts were removed and stained with hematoxylin/eosin to assess myocarditis 
severity and with Masson’s trichrome staining to detect fibrosis. Myocarditis and fibrosis 
severity scores were assessed using semi-quantitative scale (Supplement Material). 
 
RT-PCR and Real-Time RT-PCR 
RT-PCR was performed as described16 (Supplement Material). For real-time RT-PCR 
analysis, cDNA was amplified using the Power SYBR Green PCR Master Mix (Applied 
Biosystems) and oligonucleotides complementary to transcripts of the analyzed genes (Online 
Table 1). 
 
Immunocytochemistry  
Kania et al.       CIRCRESAHA/2009/196287/R2 
 
 
9 
Cells were cultured on gelatine-coated cover slips. Hearts were harvested and cell engraftment 
was analyzed on cryo- and paraffin-fixed sections. Fixation and immunostaining procedures 
were performed as described previously16 (Supplement Material).  
 
Western blotting  
Prominin-1+ cells were cultivated in vitro with TGF-β (PeproTech) for 1 hour, 3 and 7 days. 
Control cells were cultivated in the absence of TGF-β. Cell lysates were blotted and incubated 
with appropriate antibodies (Supplement Material).  
 
Flow cytometry 
Cell suspensions were stained using fluorochrome-conjugated mouse-specific antibodies 
(Supplement Material) and analyzed with a CyAn-ADP-analyzer (Beckman Coulter) using 
FlowJo software (Tree Star). Heart infiltrates were identified as CD45+ cells from heart tissue 
suspensions gated on CD45/side scatter plots as described3.  
 
Cytokine ELISA  
Heart-infiltrating mononuclear cells were isolated as described3 with slight modifications 
(Supplementary Material). Cytokine levels of IFN-γ, TNF-α,  IL-17 and TGF-β were 
measured by ELISA in supernatants of heart-infiltrating mononuclear cells (Supplement 
Material).  
 
Statistics 
The Mann-Whitney U test was used for the evaluation of non-parametrical data. Normally 
distributed data were compared using Student’s t-test. Differences were considered as 
statistically significant for p<0.05.  
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Results 
 
BM cells represent the cellular source of cardiac fibrosis in late EAM 
Accumulation of collagen-producing fibroblasts is a hallmark of pathological 
remodelling in end-stage heart failure. For addressing the contribution of the BM 
compartment to tissue fibrosis during the late stage of EAM, we created chimeric mice using 
lethally irradiated BALB/c mice reconstituted with EGFP+ syngeneic BM. Six weeks after 
BM reconstitution only few EGFP+ cells were found in healthy hearts (not shown). 
Immunization of chimeric mice with αMyHC/CFA, however, resulted in severe myocarditis 
at day 21 (Fig. 1A). Flow cytometry revealed that nearly all EGFP+ cells isolated from the 
heart of chimeric mice at this time point co-expressed CD45, suggesting an inflammatory 
phenotype (Fig. 1B). We also identified a significant fraction of prominin-1+ cells among the 
EGFP+/CD45+ heart-infiltrating cells (Fig. 1B). Nonetheless, in CFA-only immunized control 
chimeric mice, just few EGFP+ cells were observed (Fig. 1B).   
After day 21 inflammatory infiltrates largely resolved and progressive fibrosis developed by 
day 46 (Fig. 1C-F). Analysis of these fibrotic hearts demonstrated that >60% of collagen-, 
alpha smooth muscle actin (αSMA)- and fibronectin-producing fibroblasts expressed EGFP 
(Fig. 1C-E). Importantly, we observed no EGFP signal in αMyHC+ cardiomyocytes (Fig. 
1F). CFA-only immunized control chimeric mice, did not develop any fibrosis as expected 
(not shown).  
These findings indicate that the BM compartment represents the cellular source for 
both heart-infiltrating progenitor cells at the peak, as well as fibroblasts during the late stage 
of disease. 
 
Inflammatory prominin-1+ progenitor cells showed bilineage differentiation potential  
Kania et al.       CIRCRESAHA/2009/196287/R2 
 
 
11 
Next, we aimed to identify the potential fibroblast progenitors within the inflammatory 
infiltrates at the peak of disease. Analysis of inflamed hearts of immunized chimeric mice 
revealed a fraction of about 30% of EGFP+ cells co-expressing the progenitor cell marker 
prominin-1 (Fig. 1B). Nearly all prominin-1+ cells co-expressed CD45 and stem/progenitor 
cell markers c-kit, Sca-1 and Cxcr4 (Fig. 2A,B). Instead, after transition from the acute to the 
chronic phase of EAM, the number of inflammatory infiltrates dramatically decreased, and we 
found only few prominin-1+ cells in the fibrotic myocardium (not shown). 
Given the progenitor phenotype of prominin-1+ cells, we addressed their specific 
differentiation capacity. To this aim, we isolated inflammatory prominin-1+ cells from acutely 
inflamed hearts at day 21 and expanded them in vitro for 2-3 weeks. The cultured cells 
expressed prominin-1, CD45, c-kit, Sca-1 and Cxcr4 antigens and nanog, c-kit, sca-1, islet-1 
and nestin mRNA transcripts (Fig. 3A,B,G). In the presence of TGF-β, prominin-1+ cells 
acquired a fibroblast-like phenotype, expressed αSMA and fibronectin (Fig. 3C), and down-
regulated the expression of genes and proteins characteristic for stem/progenitor cells (Fig. 
3F,H). These findings demonstrate the capacity of heart-infiltrating prominin-1+ cells to 
differentiate into fibroblasts in the presence of TGF-β. 
Alternatively, prominin-1+ cells gained a large, flat morphology with granular 
cytoplasm and showed high phagocytic activity in the presence of M-CSF (Fig. 3D), 
suggesting a monocyte/macrophage phenotype. However, the prominin-1+ cells failed to up-
regulate cardiomyocyte-specific genes and proteins (Fig. 3E,H). Unlike prominin-1+/CD45+ 
cells, the prominin-1-/CD45+ cell fraction isolated from inflamed hearts showed only 
macrophage phenotype in the presence of M-CSF, but failed to differentiate into fibroblasts 
and cardiomyocytes (Online fig. 1). 
Notably, prominin-1+ cells isolated from the inflamed hearts prevented EAM 
development when intravenously injected before the onset of acute inflammation, at days 7 
and 14, into αMyHC/CFA immunized mice (Online fig. 2). 
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Prominin-1 identifies a common fibroblast/macrophage progenitor cell in EAM  
To address whether heart-infiltrating prominin-1+ cell represents a common progenitor 
for fibroblasts and monocytes/macrophages, we isolated prominin-1+ cells from inflamed 
heart of immunized BALB/c-EGFP mouse. Co-culture of 1-5 of prominin-1+/EGFP+ cells on a 
non-transgenic heart-derived feeder layer gave rise to single cell-derived EGFP+ cell-colony 
(Fig. 4A), positive for prominin-1 (Fig. 4B). Next, co-cultures containing single cell-derived 
EGFP+ clones were divided into 3 dishes containing either TGF-β, M-CSF or oxytocin. In the 
presence of TGF-β, EGFP+ cells expressed fibronectin (Fig. 4C), whereas exposure to M-CSF 
gave rise to a macrophage phenotype with phagocytic activity (Fig. 4D). In the presence of 
oxytocin, however, cells failed to assume cardiomyocyte-like phenotype, i.e. stained negative 
for αMyHC (Fig. 4E). Thus, the prominin-1+ cells represent a common progenitor for 
fibroblasts and monocytes/macrophages, but not for cardiomyocytes in the acutely inflamed 
heart.  
To test if heart-infiltrating prominin-1+ cells undoubtedly originate from BM, we 
isolated and expanded prominin-1+/EGFP+ cells from the inflamed hearts of chimeric mice 
reconstituted with EGFP+ BM. EGFP+ cells retained an undifferentiated phenotype expressing 
prominin-1 and CD45 (Online Fig. 3A,B), and upon induction of differentiation, 
differentiated into fibroblasts and monocytes/macrophages, but not into cardiomyocyte-like 
cells (Online Fig. 3C-F). 
Taken together, prominin-1 expression characterizes a common fibroblast/macrophage 
progenitor among heart-infiltrating BM-derived cells at the peak of inflammation in the EAM 
model. Consequently these prominin-1+ cells represent the potential cellular source of 
fibroblasts mediating cardiac fibrosis during the late stage of disease.  
 
TGF-β  signalling mediates fibroblast activation via Smad proteins 
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So far, we showed that TGF-β mediates fibroblast differentiation of heart-infiltrating 
prominin-1+ cells. In fact, TGF-β treated prominin-1+ cells significantly up-regulated the 
expression of genes characteristic for fibroblasts such as collagen I, αsma, fibronectin (Fig. 
5A). Activation of the TGF-β receptor complex involves phosphorylation of Smad proteins, 
which subsequently regulate transcription17. TGF-β-induced in vitro fibroblast differentiation 
of heart-infiltrating prominin-1+ cells was associated with phosphorylation of Smad proteins 
(Fig. 5B,C). Of note, phosphorylation of Smad2 (P-Smad2) occurred already 1 hour after 
TGF-β exposure. P-Smad2 expression was reduced in cells cultivated with TGF-β for 7 days 
(Fig. 5B), and maintained at low levels following differentiation (not shown). 
 
Microenvironment defines the fate of heart-infiltrating prominin-1+ progenitors in EAM 
So far, we demonstrated that in vitro differentiation of heart-infiltrating prominin-1+ 
cells into fibroblast-like cells critically depended on TGF-β. To characterize the stage-specific 
microenvironment of the inflamed heart that dictates the fate of prominin-1+ cells in vivo, we 
measured cytokine production by heart-infiltrating cells at various time points after 
immunization. Release of the pro-inflammatory cytokines: IL-17, IFN-γ, and TNF-α  by 
heart-infiltrating mononuclear infiltrates was significantly reduced at day 32 (beginning of 
fibrotic phase) compared with day 21 (inflammatory phase; Fig. 6A). In contrast, levels of 
TGF-β were markedly increased in heart tissue during the late stage of disease (Fig. 6A). 
Subsequently, we isolated the inflammatory heart-infiltrating prominin-1+ cells from EGFP+ 
mice at day 21, expanded in vitro and injected intracardially into healthy (d0), inflamed (d14), 
and fibrotic (d32) hearts. 7-14 days after intracardiac injection the mice were sacrificed and 
the hearts analyzed. 
Prominin-1+/EGFP+ cells maintained an undifferentiated phenotype after injection into 
the healthy hearts (Fig. 6B). Injection of prominin-1+/EGFP+ cells at the onset of 
inflammation (day 14) resulted in EGFP+ monocyte/macrophage differentiation at day 21 
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(Fig. 6C). Of note, some EGFP+ cells already expressed also fibronectin at this time point 
(Fig. 6C). Injection of prominin-1+/EGFP+ cells at day 32 characterized by enhanced tissue 
fibrosis, resulted in the differentiation of EGFP+ cells into collagen I-, fibronectin-, and 
αSMA-expressing fibroblasts, analyzed at day 46 (Fig. 6D).  
Taken together, these findings suggest that the stage-specific cytokine milieu dictates 
the fate of BM-derived progenitor cells in the diseased heart during EAM. 
 
TGF-β  is a critical mediator for cardiac fibrosis in EAM  
So far, our data suggest that TGF-β promotes the fibroblast differentiation of heart-
infiltrating prominin-1+ progenitor cells in the inflammatory microenvironment in the EAM 
model. Given the myriad of mediators/cytokines released during cardiac inflammation, the in 
vivo experiments described above cannot exclude that other mediator than TGF-β promotes 
tissue fibrosis independent from the prominin-1+ cells. To address the overall role of TGF-β  
in the development of cardiac fibrosis in EAM, we therefore repetitively injected α-TGF-β 
blocking antibody in mice between 17-46 days after  αMyHC/CFA immunization. Control 
mice were treated with a non-specific isotype antibody. As illustrated in figure 7, we observed 
markedly reduced fibrosis measured as collagen I-positive area in heart tissues isolated from 
mice treated with α-TGF-β  antibody (Fig. 7A,C) compared to sham-treated control animals 
(Fig. 7B,C). In addition, heart-to-body weight ratios were lower in α-TGF-β compared to 
sham-treated mice (Fig. 7D). Furthermore, fibroblast-specific differentiation was abrogated if 
heart-infiltrating prominin-1+/EGFP+ cells were injected into fibrotic myocardium of 
 αMyHC/CFA-immunized mice treated with serially administrated α-TGF-β blocking 
antibody (Online fig. 4). These findings complete our observation that α-TGF-β antibody 
blocked fibroblast differentiation of inflammatory heart-infiltrating prominin-1+ cells, 
cultivated in the presence of TGF-β (Fig. 7E,F). 
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Taken together, TGF-β critically modulates fibroblast differentiation of heart-
infiltrating prominin-1+ progenitor cells and tissue fibrosis in the EAM model. 
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Discussion  
Myocarditis predisposes to dilated cardiomyopathy, the most common cause of heart 
failure in young patients. Cardiac fibrosis is a hallmark of the failing heart, but little is known 
about the cellular origins and the underlying mechanisms of accumulating fibroblasts. Using a 
mouse model of EAM, we demonstrate that prominin-1 expression defines a specific 
population of heart-infiltrating BM-derived progenitor cells. Regulated by TGF-β, they 
differentiate into fibroblasts, thereby promoting tissue fibrosis during the late stages of 
disease. Importantly, however, these cells showed no ability to differentiate into 
cardiomyocytes.  
Fibrogenic cells can expand from at least 3 sources: 1) from local activation and 
proliferation of heart-resident mesenchymal cells, 2) by epithelial-to-mesenchymal transition, 
and 3) from BM-derived cells18. Using immunized chimera reconstituted with EGFP+ donor 
BM we illustrated that the vast majority, >60% of cardiac fibroblasts promoting fibrosis in the 
EAM model originate from BM. Given the facts that EGFP expression was detected in 80-
90% of EGFP transgenic cells (unpublished observations), and that BM-derived fibroblasts 
were not observed before the onset of cardiac inflammation, we conclude that inflammatory 
infiltrates represent the major source of cardiac fibroblasts in EAM. Nevertheless, we cannot 
exclude that endogenous cardiac fibroblasts also participate in the fibrotic process at late 
stages of EAM. Some authors postulated heart-resident fibroblasts as the major cellular source 
of tissue fibrosis associated with hypertrophy and ischemic heart failure19,20. Moreover, El-
Helou et al.21 identified heart-resident nestin-expressing fibroblast progenitors, migrating to 
the infarcted region in the response to ischemia, suggesting involvement of these cells in the 
scarring processes of the injured myocardium. 
Injured hearts are believed to dispose of a pool of endogenous/recruited progenitors 
playing a relevant role in myocardial regeneration and pathological remodelling22, but nothing 
is known about a potential role of any progenitors in EAM. We demonstrated here that at the 
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peak of EAM prominin-1+ progenitors denote a significant fraction among CD45+ heart-
infiltrating inflammatory cells. Prominin-1 is a well-established marker of haematopoietic, 
embryonic and adult progenitors16,23,24. We illustrated that heart-infiltrating prominin-1+ cells 
represent a common progenitor for fibroblasts and macrophages in EAM. However, heart-
infiltrating prominin-1+ cells showed impaired regenerative capacity (new cardiomyocytes 
formation). This is in strong contrast to prominin-1+ cells derived from healthy heart16, despite 
the high similarity regarding the expression of stem/progenitor cell markers and 
immunomodulatory properties. Thus, our findings point to careful evaluation of 
stem/progenitor cells isolated from injured organs for use in regenerative medicine. In EAM 
model, inflammation in the myocardium disables the expansion of progenitors with 
regenerative capacity from cardiac tissue. It remains still to be elucidated whether genetic or 
epigenetic manipulations can revert/induce regenerative potential in prominin-1+ cells derived 
from inflamed heart or even BM. 
 Heart injury results in leukocyte recruitment and a specific inflammatory environment, 
promoting healing processes and scar formation. Accordingly, pro-inflammatory 
cytokines/chemokines become rapidly induced in the injured myocardium. In parallel, counter 
regulatory mechanisms result in release and activation of inhibitory mediators, such as pro-
fibrotic growth factor TGF-β regulating the transition from inflammation to fibrosis25. Our 
experiments demonstrate that the stage-specific microenvironment dictates the fate of 
transplanted progenitor cells at various time points during the EAM course. Accordingly, 
prominin-1+ cells derived from inflamed and healthy (Online fig. 5) heart gained a fibroblast 
phenotype after intracardiac injection during late stages of EAM when pro-fibrotic 
cytokine/chemokine production predominates. In contrast, prominin-1+ cells, injected into 
healthy heart, did not acquire fibroblast phenotype. 
 Our observations are in line with studies on infarcted26 or hypertrophic14 hearts, which 
suggest a decisive role of the myocardial microenvironment in promoting fibroblast-specific 
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differentiation and scar formation of BM-derived cells. Similarly, it has been shown in the 
myocardial infarction model that the microenvironment promoted the differentiation of BM-
derived, recruited or administered progenitor cells into hematopoietic cell phenotypes, but not 
cardiomyocytes27,28. Together with our findings in an inflammatory heart disease model, 
current evidence supports the view that the specific microenvironment of an injured heart does 
not allow cardiac regeneration, but promotes either the accumulation of 
monocytes/macrophages or tissue fibrosis/scarring. Thus, it is not surprising that most studies 
evaluating BM-derived stem cell therapies in mouse models of myocardial infarction showed 
minimal in vivo cardiomyocyte differentiation only14,29, or questioned the regenerative 
potential of stem cell-based therapies at all27,28,30,31. Accordingly, BM-derived CD133+ 
progenitors transplanted after myocardial infarction, did not form new cardiomyocytes but 
nevertheless improved cardiac function32. Similarly, we showed that prominin-1+ progenitor 
cells expanded from both, healthy16 and inflamed hearts efficiently prevent EAM 
development, but do not contribute to the regeneration of damaged cardiac tissue. Therefore, 
the development of clinically relevant cell-based therapies requires either ex vivo 
manipulation of progenitor cells rendering them resistant to the inflammatory environment, or 
the combined in vivo targeting of specific cytokines/chemokines impairing the regenerative 
capacity of progenitor cells. In fact, ex vivo pretreatment of autologous BM-derived 
progenitor cells with cardiomyogenic growth factors potentates their cardiac differentiation 
and their functional regenerative capacity in vivo33.  
So far, several studies on models of non-inflammatory heart disease suggested a 
critical role of TGF-β in cardiac fibrosis8,37.  A broad range of different cells recruited due to 
cardiac issue injury, i.e. macrophages, T cells, and mast cells produce TGF-β2,5. In EAM, 
intra-cardiac TGF-β levels progressively increase in parallel with steadily resolving cardiac 
infiltrates. TGF-β modulates the behavior of fibroblast progenitors/mature fibroblasts by 
stimulating the synthesis of various extracellular matrix proteins including collagens, 
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fibronectin, tenascin and proteoglycans25, factors that affect the fate of progenitor cells. In our 
model, the fibroblast-specific differentiation of prominin-1+ cells depended on TGF-β, 
suggesting that this cytokine is the key mediator of cardiac fibrosis late during the EAM 
course. In fact, TGF-β signalling mediated the phosphorylation of Smad2 proteins in 
prominin-1+ progenitors, pointing to the involvement of canonical Smad-dependent signalling 
pathways19,34 in the transition of prominin-1+ progenitors to fibroblasts. Given the fact that 
TGF-β strongly promotes fibroblast differentiation of heart-infiltrating prominin-1+ cells in 
vitro, it was not surprising that prominin-1+ cells differentiated into fibroblasts after intra-
cardiac injection at late stage of EAM characterized by high levels of TGF-β release within 
the heart. Accordingly, TGF-β depletion efficiently blocked cardiac fibrosis in our model. 
Similarly, anti-TGF-β treatment markedly decreased collagen deposition in infarcted hearts35. 
Given the high frequency of heart-infiltrating progenitors in EAM, further studies are needed 
to develop strategies, which specifically block the fibroblast-specific differentiation of 
progenitor cells. Based on our data, we would expect that TGF-β dependent signalling 
pathways might become a potential target against progressive cardiac fibrosis and end-stage 
heart failure in the future.  
 In conclusion, we identified for the first time prominin-1+ bilineage fibroblast and 
monocyte/macrophage progenitors among heart-infiltrating CD45+ cells as the major cellular 
source of cardiac fibrosis in post-inflammatory heart disease. Furthermore, we proved that the 
developmental fate of heart-infiltrating prominin-1+ progenitors was dictated by a specific, 
disease stage-dependent, myocardial microenvironment. Finally, we identified TGF-β as the 
key cytokine promoting fibroblast differentiation of prominin-1+ progenitors during the 
transition from acute myocarditis to inflammatory cardiomyopathy in the EAM model. The 
critical role of prominin-1+ progenitors in the progression of cardiac inflammation to 
myocardial fibrosis identifies these cells as a promising target for novel treatment approaches 
for post-inflammatory cardiac fibrosis during non-ischemic heart failure in the future. 
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Figure legends  
Figure 1. BM-derived cells infiltrate myocardium and contribute to fibrotic tissue in EAM. 
(A) Hematoxylin/eosin-stained heart section shows myocarditis in BALB/c mouse immunized 
with αMyHC/CFA at day 21. 
(B) Flow cytometry analysis of digested hearts isolated from BALB/c and EGFP->BALB/c 
chimera mice 21 days after immunization with αMyHC/CFA or CFA-only demonstrate massive 
infiltration of EGFP+ BM-derived cells in the heart of EGFP->BALB/c chimera. Heart-
inflammatory EGFP+ cells of diseased EGFP->BALB/c chimera express CD45 and prominin-1.  
(C-F) Immunofluorescence analysis of fibrotic hearts sections (day 46) from EGFP->BALB/c 
chimera show EGFP+ BM-derived cells expressing fibronectin (C), αSMA (D) and collagen I 
(E), but not αMyHC (F). Hoechst 33342 (blue) was used for nuclear staining. Bars = 20µm. 
  
Figure 2. Inflamed heart recruits prominin-1+ progenitor cells. 
Heart-infiltrating cells, gated on prominin-1+ cell population (A), analyzed by flow cytometry at 
the peak of inflammation, showed the co-expression of CD45, c-kit, Cxcr4 and Sca-1 (B). 
 
Figure 3. Heart-infiltrating prominin-1+ cells represent a common progenitor for 
fibroblasts and macrophages.  
Heart-infiltrating prominin-1+ cells were isolated at the peak of EAM, and further expanded in 
vitro. Flow cytometry analysis showed the expression of prominin-1, CD45, c-kit, Cxcr4 and 
Sca-1 (A). Light microscopy and immunofluorescence images of in vitro expanded prominin-1+ 
cells expressing prominin-1 (B), differentiated with TGF-β into fibronectin-positive fibroblasts 
(C), or with M-CSF into phagocyting (E.coli) CD11b-positive macrophages (D). Oxytocin failed 
to induce αMyHC+ cardiomyocyte-specific differentiation (E). Hoechst 33342 (blue) was used 
to visualize cell nuclei. Bars = 20µm.  
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(F) Flow cytometry analysis of specific progenitor cell surface markers before (white bars), and 
after (black bars) induction of fibroblast differentiation of prominin-1+ cells. Bars represent mean 
± SD from three independent experiments of the percentage of cells expressing the specific 
marker. mRNA levels of genes specific for progenitor cells: nanog, sca-1, c-kit, islet-1, nestin 
(G), for cardiomyocytes: nkx2.5, αmyhc, βmyhc, myosin light chain (mlc)-2v (H), and fibroblast 
(αsma; H) in sorted heart-infiltrating prominin-1+ cells before (Prom-1+ sorted) and after 
expansion in CEM (Prom-1+ CEM), and after differentiation into fibroblast (Prom-1+ +TGF-β) 
and cardiac (Prom-1+ +oxytocin) lineages.  (+) = positive control, Heart = adult heart, PPC- 
sorted prominin-1+ cells derived form healthy hearts.  
 
Figure 4. Heart-infiltrating prominin-1+ cells are clonogenic. 
Single heart-infiltrating prominin-1+/EGFP+ cells, isolated from the inflamed heart of BALB/c-
EGFP mouse at day 21, plated on EGFP-negative feeder layer formed clones (A) expressing 
prominin-1 (B). Following stimulation with TGF-β, EGFP+ cells differentiated into fibronectin-
expressing fibroblasts (C), M-CSF promoted differentiation into phagocyting (E.coli) 
macrophages (D), but treatment with oxytocin failed to induce the expression of cardiomyocyte 
marker-αMyHC (E). Hoechst 33342 (blue) was used to visualize cell nuclei. Bars = 20µm. 
 
Figure 5. TGF-β  mediates fibroblast differentiation of heart-infiltrating prominin-1+ cells 
in vitro. 
Heart-infiltrating prominin-1+ cells cultivated in vitro in the presence of TGF-β for 1 hour, 3 and 
7 days. (A) Gene expression levels assessed by Real-Time RT-PCR. Bars represent mean ± SD 
from at least 5 individual cell cultures. (B) Western blotting analysis of Smad2 phosphorylation 
(P-Smad2). (C) The quantification of P-Smad2 to Smad2/3 immunoreactivity. Control cells were 
cultivated in the absence of TGF-β. Bars represent mean ± SD from 3 individual experiments. 
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Figure 6. The stage-specific cytokine milieus determine differentiation of heart-infiltrating 
prominin-1+ cells in EAM. 
(A) Cytokine production of stimulated cardiac mononuclear cells isolated from inflamed hearts 
at the peak of inflammation (d21, white bars) and from fibrotic hearts (d32, black bars). Healthy 
heart tissue (d0, grey bars) was used as a control. Each bar represents a mean ± SD of 5 different 
culture wells. One out of several representative experiments is shown.  
(B-D) Prominin-1+/EGFP+ cells, isolated from the inflamed heart of BALB/c-EGFP mouse at 
day 21, were expanded in vitro and intracardially injected into healthy (day 0), inflamed (day 14) 
and fibrotic heart (day 32) of BALB/c mice; and were analyzed 7-14 days after injection. 
Prominin-1+/EGFP+ cells injected into healthy hearts retained an undifferentiated phenotype co-
expressing prominin-1 and CD45 (B). In the inflammatory microenvironment prominin-
1+/EGFP+ cells gained expression of macrophage-specific F4/80, and few expressed fibronectin 
(C). In the fibrotic heart, EGFP+ cells expressed fibroblast-specific collagen I, fibronectin and 
αSMA (D). Differentiation of EGFP+ cells into αMyHC-positive cardiomyocytes was not 
observed at any stage. Hoechst 33342 (blue) was used to visualize cell nuclei. Bars = 20µm. 
 
Figure 7. TGF-β  is critical for cardiac fibrosis development after EAM.  
TGF-β production was blocked with a neutralizing α-TGF-β antibody injected in αMyHC/CFA-
immunized BALB/c mice between days 17-46 after immunization. Control BALB/c mice 
received a non-specific isotype control antibody. Heart tissue sections were stained with 
Masson’s trichrome and analyzed at day 46 after αMyHC/CFA immunization. Fibrotic areas 
were observed in sham-treated mice (B,C), but not in animals treated with α-TGF-β (A,C). 
Individual scores for each treatment group are shown. Heart-to-body weight (HW/BW) ratios for 
αMyHC/CFA-immunized mice treated with α-TGF-β vs. sham (D). Individual values and 
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average for each group are shown. Heart-infiltrating prominin-1+ cells cultivated in vitro with 
TGF-β  failed to differentiate into fibronectin-positive fibroblasts when cultured with α-TGF-
β blocking antibody (E) but not with PBS (F). 
Figure 1; Kania et al.
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